Cover Image
市場調查報告書

異位性皮膚炎治療藥的全球市場的未來預測

Global Atopic Dermatitis Drugs Market Forecast 2019-2027

出版商 Inkwood Research 商品編碼 626309
出版日期 內容資訊 英文 130 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
異位性皮膚炎治療藥的全球市場的未來預測 Global Atopic Dermatitis Drugs Market Forecast 2019-2027
出版日期: 2018年10月08日 內容資訊: 英文 130 Pages
簡介

本報告提供全球異位性皮膚炎治療藥的市場未來展望相關分析,跟系統概要和市場結構,主要的推動及阻礙市場要素,整體市場規模趨勢預測 (今後9年份),各作用機制、各類藥物、各地區的詳細趨勢,相關產業的關聯結構與市場機會,市場競爭環境,主要企業簡介等調查。

第1章 分析範圍

第2章 分析方法

第3章 摘要整理

第4章 市場動態

  • 簡介:異位性皮膚炎
  • 市場定義和範圍
  • 法律上、政策上、規定上的課題
  • 推動市場要素
  • 阻礙市場要素
  • 市場機會
  • 課題

第5章 各作用機制 (ROA) 的市場

  • 外用製劑
  • 口服藥
  • 注射藥

第6章 各類藥物的市場

  • 局部性抗生素
  • 局部性抗組織胺藥物
  • 局部性皮質類固醇
  • 局部性保濕劑/軟化劑
  • 局部性CALCINEURIN
  • 免疫調節藥物
  • 非適應症 (非標籤藥物) 療法
  • 全身性的醫藥品
  • PDE-4抑制劑
  • 白細胞介素抑制劑

第7章 主要分析指標

  • 波特的五力分析
  • 市場機會矩陣
  • 供應商環境
  • 開發平台分析

第7章 各地區分析

  • 北美 (美國,加拿大)
  • 歐洲 (德國,法國,英國,俄羅斯等)
  • 亞太地區 (印度,中國,日本,澳洲、紐西蘭,韓國等)
  • 其他的國家 (RoW:南美,中東、非洲)

第9章 企業簡介

  • ALLERGAN PLC.
  • AQUA PHARMACEUTICALS (ALMIRALL COMPANY的子公司)
  • Astellas Pharma Inc.
  • BAYER AG
  • BIOFRONTERA AG
  • BRISTOL-MYERS SQUIBB
  • STIEFEL LABORATORIES INC
  • ENCORE DERMATOLOGY
  • GALDERMA SA
  • LEO PHARMA
  • MEDA PHARMACEUTICALS (MYLAN)
  • NOVARTIS AG
  • PFIZER
  • REGENERON PHARMACEUTICALS
  • SANOFI SA
  • VALENT PHARMACEUTICAL INC.

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 16698

KEY FINDINGS

According to market expectations, the global atopic dermatitis drugs market should grow with a CAGR of 4.77% over the forecast period. The base year considered for the study is 2017 and the forecast period is 2019-2027.

The global atopic dermatitis drugs market is primarily driven by factors such as the increasing prevalence of food allergies causing atopic dermatitis, the rising focus on systematic therapies and the ever increasing use of pharmacological products in developing countries

MARKET INSIGHTS

The important driver increasing growth in the global atopic dermatitis drugs market is the high prevalence of food allergies exacerbating atopic dermatitis. It is estimated that food allergy and severe atopic dermatitis coexist in about one-third of all children with atopic dermatitis. The atopic dermatitis drugs market is broadly classified into two segments on the basis of drug classes and the route of administration.

REGIONAL INSIGHTS

This report broadly segregates the atopic dermatitis drug market into four geographies namely-Europe, Asia-Pacific, North America and Rest of the World. The atopic dermatitis drugs market in North America is expected to hold the largest share by 2027. This sudden yet steady growth in the North American regional market is attributed to the high prevalence of allergic conditions in the existing population. The United States holds the largest revenue share in global atopic dermatitis drugs market country-wise.

COMPETITIVE INSIGHTS

Leading players in the global atopic dermatitis drug market are Allergan Plc, Aqua Pharmaceuticals (An Almirall Company), Astellas Pharma Inc., Bayer Ag, Biofrontera Ag,Bristol-Myers Squibb,Stiefel Laboratories Inc, Encore Dermatology, Galderma Sa, Leo Pharma, Meda Pharmaceuticals (Mylan N.V.),Novartis Ag, Pfizer, Regeneron Pharmaceuticals, Sanofi Sa, Valent Pharmaceutical Inc. and several others.

Table of Contents

1. RESEARCH SCOPE

  • 1.1. STUDY GOALS
  • 1.2. SCOPE OF THE MARKET STUDY
  • 1.3. WHO WILL FIND THIS REPORT USEFUL?
  • 1.4. STUDY AND FORECASTING YEARS

2. RESEARCH METHODOLOGY

  • 2.1. SOURCES OF DATA
    • 2.1.1. SECONDARY DATA
    • 2.1.2. PRIMARY DATA
  • 2.2. TOP-DOWN APPROACH
  • 2.3. BOTTOM-UP APPROACH
  • 2.4. DATA TRIANGULATION

3. EXECUTIVE SUMMARY

  • 3.1. MARKET SUMMARY
  • 3.2. KEY FINDINGS
    • 3.2.1. NORTH AMERICA GENERATED LARGEST CHUNK OF THE GLOBAL REVENUE
    • 3.2.2. TOPICAL ROUTE OF ADMINISTRATION HOLDS MAJORITY OF THE OVERALL MARKET SHARE
    • 3.2.3. INTERLEUKIN INHIBITOR MARKET IS ANTICIPATED TO GENERATE HIGHEST REVENUE

4. MARKET DETERMINANTS

  • 4.1. MARKET DRIVERS
    • 4.1.1. GROWING PREVALENCE OF FOOD ALLERGIES EXACERBATING ATOPIC DERMATITIS
    • 4.1.2. GROWING FOCUS ON SYSTEMATIC THERAPIES
    • 4.1.3. INCREASING USE OF PHARMACOLOGICAL PRODUCTS IN DEVELOPING COUNTRIES
  • 4.2. MARKET RESTRAINTS
    • 4.2.1. STRINGENT REGULATIONS FOR PRODUCT APPROVAL
    • 4.2.2. GENERIC COMPETITION
  • 4.3. MARKET OPPORTUNITIES
    • 4.3.1. INCREASING M&A LEADING TO MARKET CONSOLIDATION
    • 4.3.2. LAUNCH OF FIRST BIOLOGIC FOR ATOPIC DERMATITIS
    • 4.3.3. GROWING FOCUS ON NOVEL DRUGS
  • 4.4. MARKET CHALLENGES
    • 4.4.1. BLACK BOX WARNING FOR ELIDEL AND PROTOPIC
    • 4.4.2. HIGHLY GENERICIZED MARKET
    • 4.4.3. POOR PATIENT ADHERENCE DUE TO INADEQUATE INFORMATION ON DRUG USAGE

5. MARKET SEGMENTATION

  • 5.1. MARKET BY ROUTE OF ADMINISTRATION (ROA) 2019-2027
    • 5.1.1. TOPICAL
    • 5.1.2. ORAL
    • 5.1.3. INJECTIBLES
  • 5.2. MARKET BY DRUG CLASS 2019-2027
    • 5.2.1. TOPICAL ANTIBIOTICS
    • 5.2.2. TOPICAL ANTIHISTAMINES
    • 5.2.3. TOPICAL CORTICOSTEROIDS
    • 5.2.4. TOPICAL MOISTURIZERS/EMOLLIENTS
    • 5.2.5. TOPICAL CALCINEURIN INHIBITORS
    • 5.2.6. IMMUNOMODULATORS
    • 5.2.7. OFF-LABEL THERAPIES
    • 5.2.8. SYSTEMIC AGENTS
    • 5.2.9. PDE4 INHIBITOR
    • 5.2.10. INTERLEUKIN INHIBITOR

6. KEY ANALYTICS

  • 6.1. PORTERS FIVE FORCES ANALYSIS
    • 6.1.1. THREAT OF NEW ENTRANTS
    • 6.1.2. THREAT OF SUBSTITUTE
    • 6.1.3. BARGAINING POWER OF SUPPLIERS
    • 6.1.4. BARGAINING POWER OF BUYERS
    • 6.1.5. THREAT OF COMPETITIVE RIVALRY
  • 6.2. OPPORTUNITY MATRIX
  • 6.3. PIPELINE ANALYSIS
  • 6.4. LEGAL, POLICY AND REGULATORY ISSUES

7. GEOGRAPHICAL ANALYSIS

  • 7.1. NORTH AMERICA
    • 7.1.1. THE UNITED STATES
    • 7.1.2. CANADA
  • 7.2. EUROPE
    • 7.2.1. GERMANY
    • 7.2.2. FRANCE
    • 7.2.3. THE UNITED KINGDOM
    • 7.2.4. RUSSIA
    • 7.2.5. ITALY
    • 7.2.6. REST OF EUROPE
  • 7.3. ASIA-PACIFIC
    • 7.3.1. INDIA
    • 7.3.2. CHINA
    • 7.3.3. JAPAN
    • 7.3.4. AUSTRALIA AND NEW ZEALAND
    • 7.3.5. SOUTH KOREA
    • 7.3.6. REST OF ASIA PACIFIC
  • 7.4. REST OF WORLD
    • 7.4.1. LATIN AMERICA
    • 7.4.2. MIDDLE EAST AND AFRICA

8. COMPANY PROFILES

  • 8.1. ALLERGAN PLC
    • 8.1.1. COMPANY OVERVIEW
    • 8.1.2. PRODUCT PORTFOLIO
    • 8.1.3. SWOT ANALYSIS
    • 8.1.4. STRATEGIC INITIATIVES
  • 8.2. AQUA PHARMACEUTICALS (AN ALMIRALL COMPANY)
    • 8.2.1. COMPANY OVERVIEW
    • 8.2.2. PRODUCT PORTFOLIO
    • 8.2.3. SWOT ANALYSIS
  • 8.3. ASTELLAS PHARMA INC.
    • 8.3.1. COMPANY OVERVIEW
    • 8.3.2. PRODUCT PORTFOLIO
    • 8.3.3. SWOT ANALYSIS
    • 8.3.4. STRATEGIC INITIATIVES
  • 8.4. BAYER AG
    • 8.4.1. COMPANY OVERVIEW
    • 8.4.2. PRODUCT PORTFOLIO
    • 8.4.3. SWOT ANALYSIS
    • 8.4.4. STRATEGIC INITIATIVES
  • 8.5. BIOFRONTERA AG
    • 8.5.1. COMPANY OVERVIEW
    • 8.5.2. PRODUCT PORTFOLIO
    • 8.5.3. SWOT ANALYSIS
  • 8.6. BRISTOL-MYERS SQUIBB
    • 8.6.1. COMPANY OVERVIEW
    • 8.6.2. PRODUCT PORTFOLIO
    • 8.6.3. SWOT ANALYSIS
  • 8.7. STIEFEL LABORATORIES, INC
    • 8.7.1. COMPANY OVERVIEW
    • 8.7.2. PRODUCT PORTFOLIO
    • 8.7.3. SWOT ANALYSIS
  • 8.8. ENCORE DERMATOLOGY
    • 8.8.1. COMPANY OVERVIEW
    • 8.8.2. PRODUCT PORTFOLIO
    • 8.8.3. SWOT ANALYSIS
    • 8.8.4. STRATEGIC INITIATIVES
  • 8.9. GALDERMA SA
    • 8.9.1. COMPANY OVERVIEW
    • 8.9.2. PRODUCT PORTFOLIO
    • 8.9.3. SWOT ANALYSIS
    • 8.9.4. STRATEGIC INITIATIVES
  • 8.10. LEO PHARMA
    • 8.10.1. COMPANY OVERVIEW
    • 8.10.2. PRODUCT PORTFOLIO
    • 8.10.3. SWOT ANALYSIS
    • 8.10.4. STRATEGIC INITIATIVES
  • 8.11. MEDA PHARMACEUTICALS (MYLAN N.V.)
    • 8.11.1. COMPANY OVERVIEW
    • 8.11.2. PRODUCT PORTFOLIO
    • 8.11.3. SWOT ANALYSIS
    • 8.11.4. STRATEGIC INITIATIVES
  • 8.12. NOVARTIS AG
    • 8.12.1. COMPANY OVERVIEW
    • 8.12.2. PRODUCT PORTFOLIO
    • 8.12.3. SWOT ANALYSIS
    • 8.12.4. STRATEGIC INITIATIVES
  • 8.13. PFIZER
    • 8.13.1. COMPANY OVERVIEW
    • 8.13.2. PRODUCT PORTFOLIO
    • 8.13.3. SWOT ANALYSIS
    • 8.13.4. STRATEGIC INITIATIVES
  • 8.14. REGENERON PHARMACEUTICALS
    • 8.14.1. COMPANY OVERVIEW
    • 8.14.2. PRODUCT PORTFOLIO
    • 8.14.3. SWOT ANALYSIS
    • 8.14.4. STRATEGIC INITIATIVES
  • 8.15. SANOFI SA
    • 8.15.1. COMPANY OVERVIEW
    • 8.15.2. PRODUCT PORTFOLIO
    • 8.15.3. SWOT ANALYSIS
    • 8.15.4. STRATEGIC INITIATIVES
  • 8.16. VALENT PHARMACEUTICAL INC.
    • 8.16.1. COMPANY OVERVIEW
    • 8.16.2. PRODUCT PORTFOLIO
    • 8.16.3. SWOT ANALYSIS

TABLE LIST

  • TABLE 1 GLOBAL ATOPIC DERMATITIS DRUGS MARKET BY GEOGRAPHY 2019-2027 ($ MILLION)
  • TABLE 2 RECENT MERGERS AND ACQUISITIONS IN ATOPIC DERMATITIS DRUGS MARKET
  • TABLE 3 GLOBAL ATOPIC DERMATITIS DRUGS MARKET BY ROA 2019-2027 ($ MILLION)
  • TABLE 4 GLOBAL ATOPIC DERMATITIS DRUGS MARKET IN TOPICAL ROA BY GEOGRAPHY 2019-2027 ($ MILLION)
  • TABLE 5 GLOBAL ATOPIC DERMATITIS DRUGS MARKET IN ORAL ROA BY GEOGRAPHY 2019-2027 ($ MILLION)
  • TABLE 6 GLOBAL ATOPIC DERMATITIS DRUGS MARKET IN INJECTIBLES ROA BY GEOGRAPHY 2019-2027 ($ MILLION)
  • TABLE 7 GLOBAL ATOPIC DERMATITIS DRUGS MARKET BY DRUG CLASS 2019-2027 ($ MILLION)
  • TABLE 8 GLOBAL ATOPIC DERMATITIS DRUGS MARKET IN TOPICAL ANTIBIOTICS BY GEOGRAPHY 2019-2027 ($ MILLION)
  • TABLE 9 GLOBAL ATOPIC DERMATITIS DRUGS MARKET IN TOPICAL ANTIHISTAMINES BY GEOGRAPHY 2019-2027 ($ MILLION)
  • TABLE 10 GLOBAL ATOPIC DERMATITIS DRUGS MARKET IN TOPICAL CORTICOSTEROIDS BY GEOGRAPHY 2019-2027 ($ MILLION)
  • TABLE 11 GLOBAL ATOPIC DERMATITIS DRUGS MARKET IN TOPICAL MOISTURIZERS/EMOLLIENTS BY GEOGRAPHY 2019-2027 ($ MILLION)
  • TABLE 12 GLOBAL ATOPIC DERMATITIS DRUGS MARKET IN TOPICAL CALCINEURIN INHIBITORS BY GEOGRAPHY 2019-2027 ($ MILLION)
  • TABLE 13 GLOBAL ATOPIC DERMATITIS DRUGS MARKET IN IMMUNOMODULATORS BY GEOGRAPHY 2019-2027 ($ MILLION)
  • TABLE 14 GLOBAL ATOPIC DERMATITIS DRUGS MARKET IN OFF-LABEL THERAPIES BY GEOGRAPHY 2019-2027 ($ MILLION)
  • TABLE 15 GLOBAL ATOPIC DERMATITIS DRUGS MARKET IN SYSTEMIC AGENTS BY GEOGRAPHY 2019-2027 ($ MILLION)
  • TABLE 16 GLOBAL ATOPIC DERMATITIS DRUGS MARKET IN PDE4 INHIBITOR BY GEOGRAPHY 2019-2027 ($ MILLION)
  • TABLE 17 GLOBAL ATOPIC DERMATITIS DRUGS MARKET IN INTERLEUKIN INHIBITOR BY GEOGRAPHY 2019-2027 ($ MILLION)
  • TABLE 18 PIPELINE PORTFOLIO OF DIABETES DRUGS MARKET
  • TABLE 19 REGULATORY FRAMEWORK IN ATOPIC DERMATITIS MARKET
  • TABLE 20 GLOBAL ATOPIC DERMATITIS DRUGS MARKET BY GEOGRAPHY 2019-2027 ($ MILLION)
  • TABLE 21 NORTH AMERICA ATOPIC DERMATITIS DRUGS MARKET BY COUNTRY 2019-2027 ($ MILLION)
  • TABLE 22 EUROPE ATOPIC DERMATITIS DRUGS MARKET BY COUNTRY 2019-2027 ($ MILLION)
  • TABLE 23 ASIA-PACIFIC ATOPIC DERMATITIS DRUGS MARKET BY COUNTRY 2019-2027 ($ MILLION)
  • TABLE 24 REST OF THE WORLD ATOPIC DERMATITIS DRUGS MARKET 2019-2027 (IN $ MILLION)

FIGURES LIST

  • FIGURE 1 GLOBAL ATOPIC DERMATITIS DRUGS MARKET 2019-2027 ($ MILLION)
  • FIGURE 2 THE UNITED STATES ATOPIC DERMATITIS DRUGS MARKET 2019-2027 ($ MILLION)
  • FIGURE 3 CANADA ATOPIC DERMATITIS DRUGS MARKET 2019-2027 ($ MILLION)
  • FIGURE 4 GERMANY ATOPIC DERMATITIS DRUGS MARKET 2019-2027 ($ MILLION)
  • FIGURE 5 FRANCE ATOPIC DERMATITIS DRUGS MARKET 2019-2027 ($ MILLION)
  • FIGURE 6 THE UNITED KINGDOM ATOPIC DERMATITIS DRUGS MARKET 2019-2027 ($ MILLION)
  • FIGURE 7 RUSSIA ATOPIC DERMATITIS DRUGS MARKET, 2019-2027 ($ MILLION)
  • FIGURE 8 ITALY ATOPIC DERMATITIS DRUGS MARKET, 2019-2027 ($ MILLION)
  • FIGURE 9 REST OF EUROPE ATOPIC DERMATITIS DRUGS MARKET 2019-2027 ($ MILLION)
  • FIGURE 10 INDIA ATOPIC DERMATITIS DRUGS MARKET 2019-2027 ($ MILLION)
  • FIGURE 11 CHINA ATOPIC DERMATITIS DRUGS MARKET 2019-2027 ($ MILLION)
  • FIGURE 12 JAPAN ATOPIC DERMATITIS DRUGS MARKET 2019-2027 ($ MILLION)
  • FIGURE 13 AUSTRALIA AND NEW ZEALAND ATOPIC DERMATITIS DRUGS MARKET 2019-2027 ($ MILLION)
  • FIGURE 14 SOUTH KOREA ATOPIC DERMATITIS DRUGS MARKET 2019-2027 ($ MILLION)
  • FIGURE 15 REST OF ASIA PACIFIC ATOPIC DERMATITIS DRUGS MARKET 2019-2027 ($ MILLION)
  • FIGURE 16 LATIN AMERICA ATOPIC DERMATITIS DRUGS MARKET 2019-2027 (IN $ MILLION)
  • FIGURE 17 MIDDLE EAST AND AFRICA ATOPIC DERMATITIS DRUGS MARKET 2019-2027 (IN $ MILLION)
Back to Top